Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts
China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...
Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development
Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD...
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE
China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...
Suzhou Teligene Ltd Plans IPO on Shanghai STAR Market for Cancer Drug Development
China-based Suzhou Teligene Ltd has announced plans for an initial public offering (IPO) of 63.52...
BrightGene Bio-Medical Technology Gains NMPA Approval for Oseltamivir Dry Suspension
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced receiving market approval from the...
Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial
Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...
BeiGene’s Tislelizumab Accepted for Review in Gastric Cancer Treatment
BeiGene (NASDAQ: BGNE) announced that a supplementary Biologic License Application (sBLA) for its programmed death-1...
Zelgen’s Jakitinib Phase III Study Meets Primary Endpoint for Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical study (ZGJAK016)...
Nanjing CRO Caremo Secures RMB 150 Million in Series A Round
Nanjing-based Contract Research Organization (CRO) Caremo has reportedly secured RMB 150 million (USD 22.3 million)...
Lee’s Pharmaceutical Wins NMPA Approval for ALS Drug Teglutik
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has announced receiving market approval from the National...
Winsan Medical Acquires 52% Stake in Goodfeel Dental Clinic for RMB 156 Million
China-based Winsan (Chengdu) Medical Science and Technology Co., Ltd (SHA: 600767) is set to acquire...
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
China NT Pharma Group Inks Licensing Deal for Orticumab in Asia
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with...
Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share
China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering...
Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation
Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a...
Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment
Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...